Executive Summary
Artificial intelligence (AI) is becoming embedded across pharmaceutical research, clinical development, manufacturing, medical affairs, pharmacovigilance, and commercial operations. As adoption expands, however, the strategic question is shifting from whether pharma companies should use AI to how they can deploy it safely, reliably, and at scale.
AI risks extend well beyond inaccurate outputs. Poor-quality data can undermine models, biased systems can affect decisions, cybersecurity vulnerabilities can expose sensitive information, and insufficient oversight can create regulatory and operational consequences. Generative and agentic AI introduce additional challenges as systems increasingly produce content, interact with enterprise tools, and execute workflows.
For executives, AI risk management should therefore be treated as an enterprise capability rather than an IT control. The objective is not to eliminate AI risk, but to understand where it originates, establish proportionate safeguards, and match human oversight to the potential impact of each application.
Organizations that build responsible AI capabilities alongside AI adoption will be better positioned to scale the technology while protecting patients, intellectual property, compliance, and enterprise trust.
Key Themes
- AI risk spans scientific, operational, regulatory, and commercial functions
- Data quality and model reliability directly influence AI outcomes
- Generative and agentic AI introduce new operational risks
- Cybersecurity and intellectual property require stronger AI controls
- Governance must evolve as AI adoption and autonomy increase
1. What Is the Risk of Poor-Quality Data in Pharmaceutical AI?
AI systems are only as reliable as the data used to develop and operate them. Pharmaceutical organizations work with fragmented information across clinical trials, electronic health records (EHRs), laboratory systems, manufacturing environments, and commercial platforms.
Incomplete, inconsistent, outdated, or poorly governed data can produce unreliable outputs even when the underlying model is sophisticated.
Executives should therefore treat data quality as an AI risk issue, with particular attention to:
- Data provenance and lineage
- Representativeness
- Interoperability
- Metadata quality
- Dataset completeness
2. How Can AI Model Errors Affect Pharmaceutical Decisions?
AI can generate incorrect predictions, classifications, recommendations, or content. The consequences become more significant when systems support clinical development, safety analysis, manufacturing quality, scientific research, or other high-impact activities.
The risk increases when users assume sophisticated models are inherently accurate.
Organizations should establish expectations around validation, performance monitoring, uncertainty, and human review. AI outputs should be evaluated according to their potential impact rather than their technical sophistication.
3. Why Is AI Bias a Strategic Risk for Pharma?
AI models can reproduce or amplify biases within training data, study populations, historical decisions, or system design. This is particularly important when AI is applied to patient populations, clinical research, treatment insights, or healthcare outcomes.
A model can perform well overall while producing weaker results for specific populations.
Pharma organizations should therefore evaluate performance across relevant populations and determine whether training and validation data adequately represent the intended use case. Fairness and representativeness should become part of AI validation rather than an afterthought.
4. How Could AI Create Regulatory and Compliance Risks?
Pharmaceutical AI applications can intersect with requirements covering clinical research, manufacturing, pharmacovigilance, privacy, quality systems, and regulatory submissions.
A key challenge is demonstrating that AI-supported outputs are appropriately validated, controlled, documented, and overseen.
Executives should connect AI governance with existing quality and compliance frameworks rather than creating separate processes.
Priority areas include:
- Intended-use documentation
- Validation and testing
- Auditability
- Change management
- Human oversight
5. What Cybersecurity Risks Increase With Pharmaceutical AI?
AI can expand the attack surface across organizations handling proprietary research, clinical data, manufacturing information, and confidential business content. Generative and agentic systems create additional exposure when they connect to enterprise applications, databases, external tools, or automated workflows.
Potential risks include unauthorized access, malicious inputs, compromised integrations, and inappropriate system actions.
AI security should therefore extend beyond the model itself. Identity management, access controls, data protection, secure integrations, and continuous monitoring remain essential.
6. Why Is Intellectual Property Exposure a Major AI Risk?
Pharmaceutical companies hold highly valuable intellectual property, including drug targets, molecular structures, clinical datasets, research findings, manufacturing processes, and strategic information.
Poorly controlled AI tools can create risks around how sensitive information is submitted, stored, processed, or accessed.
Executives should establish clear policies governing what employees and AI systems can access and where sensitive information can be processed. AI adoption should reinforce existing intellectual-property protection rather than create a parallel risk environment.
7. How Does Generative AI Create New Content Risks?
Generative AI can produce convincing but inaccurate scientific summaries, regulatory content, medical information, code, and business analysis. The danger is particularly high when fluent output is mistaken for verified information.
Organizations should distinguish between low-risk productivity applications and use cases where generated content could influence patients, regulators, scientific conclusions, or major business decisions.
Important safeguards include:
- Human review for high-impact outputs
- Approved enterprise AI environments
- Source verification
- Usage restrictions
- Output monitoring
The key question is not whether generative AI can produce useful content, but where that content can safely enter a pharmaceutical workflow.
8. What Risks Emerge When AI Becomes More Autonomous?
Agentic AI can increasingly plan tasks, retrieve information, use tools, and execute multi-step workflows. This changes the risk profile from AI that recommends actions to AI that can potentially take them.
Greater autonomy can improve productivity, but it also increases the consequences of incorrect instructions, excessive permissions, or unexpected behavior.
Pharma leaders should define autonomy according to risk. High-impact workflows may require approval gates, restricted permissions, transaction limits, monitoring, and escalation mechanisms.
The more authority an AI system receives, the stronger its controls need to become.
9. Why Can AI Vendor Dependencies Become a Risk?
Pharmaceutical companies increasingly rely on external AI models, cloud infrastructure, software platforms, and data providers. These relationships can accelerate adoption while creating dependencies that may be difficult to control.
Changes to an external model, service availability, security posture, data practices, or pricing can affect downstream operations.
AI procurement should therefore evaluate more than functionality and cost. Executives should consider security, data handling, transparency, continuity, portability, and exit strategies.
10. What Happens When AI Governance Cannot Scale?
One of the biggest strategic risks is allowing AI adoption to outpace governance. Different functions may independently deploy models, copilots, applications, and automation without consistent standards for validation, monitoring, ownership, or retirement.
This creates a fragmented AI environment that becomes increasingly difficult to oversee.
Effective governance should establish:
- Clear ownership and accountability
- Risk-based AI classification
- Model inventories
- Validation requirements
- Monitoring and incident processes
The objective is not to control every experiment centrally, but to apply appropriate governance according to potential impact.
Strategic Implications for Pharmaceutical Executives
AI risk management cannot sit solely with IT or compliance. Risks span scientific integrity, patient safety, cybersecurity, intellectual property, regulatory compliance, operational continuity, and reputation.
Executives should adopt a risk-based AI operating model that evaluates each application according to:
- Potential impact if it fails
- Sensitivity of the data involved
- Degree of AI autonomy
- Regulatory significance
- Ability to validate and monitor performance
- Required level of human oversight
This creates proportional governance. A low-risk productivity application should not face the same controls as an AI system supporting a safety-critical or regulated process.
What Will Define the Future of Pharmaceutical AI Risk Management?
AI risk management will become more dynamic as models become more capable, interconnected, and autonomous. One-time approvals may be insufficient for systems that change over time or interact with multiple enterprise applications.
Pharmaceutical organizations will increasingly need continuous assurance rather than static validation.
Future priorities are likely to include:
- Continuous AI performance monitoring
- AI-specific cybersecurity controls
- Agentic AI permission frameworks
- Automated risk detection
- Integrated AI governance platforms
- Stronger alignment between AI governance and quality systems
Key Takeaways
- Poor-quality data can undermine sophisticated AI systems
- Model errors can create scientific and operational consequences
- Bias can affect performance across patient populations
- AI validation and traceability are critical in regulated environments
- AI expands cybersecurity and data-protection risks
- Intellectual property requires stronger controls
- Generative AI outputs require verification in high-impact workflows
- Agentic AI increases risk as systems gain autonomy
- Third-party dependencies can create governance and continuity risks
- Scalable governance is essential for responsible AI adoption
Conclusion
AI offers pharmaceutical companies significant opportunities across discovery, development, manufacturing, evidence generation, and commercial operations. But realizing that value depends on managing the risks that accompany increasingly capable systems.
The risks are interconnected. Poor data can undermine model performance, weak governance can allow unreliable systems into sensitive workflows, and greater autonomy can increase operational exposure. At the same time, cybersecurity and intellectual-property weaknesses can create consequences far beyond the technology itself.
For pharmaceutical executives, AI risk management should therefore be viewed as an enabler of scale. The objective is not to slow innovation through excessive controls, but to create the confidence required to move AI from experimentation into critical scientific and business processes.
Organizations that combine strong data foundations, risk-based governance, cybersecurity, validation, human oversight, and continuous monitoring will be better positioned to capture AI’s value while protecting patients, intellectual property, regulatory standing, and long-term enterprise trust.
Artificial intelligence is rapidly becoming part of the Pharmaceutical industry’s drug discovery, clinical development, manufacturing, regulatory and commercial operations. AI can accelerate research and improve efficiency, but its growing use also introduces risks that executives must understand and manage.
The FDA and EMA released 10 guiding principles for good AI practice in drug development in 2026, emphasizing human-centric design, risk-based approaches, data governance, model assessment and lifecycle management.
Pharmaceutical Data Quality and Bias
AI systems depend heavily on the quality of their training and input data. Incomplete, inconsistent or biased datasets can produce unreliable results.
For Pharmaceutical companies, this can become particularly important when AI is used to analyze clinical, real-world or patient data.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
